Satellos Bioscience Inc (MSCLF)

$0.43 +0.02 (5.83%)
Market Cap 74.12M
Revenue (ttm) 0.00
Net Income (ttm) -20.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 82,100
Avg Vol 80,948
Day's Range N/A - N/A
Shares Out 176.31M
Stochastic %K 0%
Beta 0.95
Analysts Sell
Price Target $0.86

Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an...

Industry: Biotechnology
Sector: Healthcare
Address:
Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
Florestan
Florestan Jul. 16 at 4:05 PM
$DTIL 3 things to keep in mind for the DMD program which I believe will hit commercialization before the HBV program. 1. It will be a functional cure for about 60% of the patients. Depending on the level of penetration the patient may or may not have to take another drug which I will mention below. 2. If they are going after muscle stem cell editing, they will restore asymmetric division by allowing dystrophin to form the polarity scaffolding (green DMD curve). I'm kind enough to attach an image to show you how this works. 3. The speed of the program. It will only take 3-4 months to show functional benefit if polarity deficit is restored (evident by $MSCLF's peer-reviewed work, and their own P2 timeline). GLTA.
1 · Reply
Florestan
Florestan Jul. 16 at 3:58 PM
$DTIL's preclinical data achieved through muscle stem cell editing and $MSCLF's complete restoration of muscles for the canines through fixing stem cell polarity are pointing to the same directions. You fix DMD through fixing muscle stem cells. Period. Every other approach will fail and that opens up a big short opportunity in every DMD names that aren't targeting muscle stem cells.
0 · Reply
Florestan
Florestan Jul. 16 at 1:27 PM
$MSCLF Satellos Bioscience Inc., developing a small molecule to restore asymmetric division in stem cells in vivo to treat Duchenne, announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer (“CMO”). Dr. Farwell joins Satellos from Dyne Therapeutics (Nasdaq: $DYN), where he most recently served as CMO and medical advisor. Satellos will be submitting IND-enabling package to global regulators this quarter to begin Phase 2 in an RCT setting to prove the hypothesis that the lack of dystrophin in muscle stem cell is causing impaired regeneration, thus explaining the progressively fatal nature of the disease. https://ir.satellos.com/news/news-details/2025/Satellos-Appoints-Dr--Wildon-Farwell-as-Chief-Medical-Officer/default.aspx
0 · Reply
Florestan
Florestan Jul. 14 at 3:54 PM
$MSCLF "Our study provides in vivo validation that dystrophin-deficient MuSCs undergo fewer asymmetric cell divisions, instead favouring symmetric expansion." https://onlinelibrary.wiley.com/doi/full/10.1002/jcsm.13682 This is why none of the gene therapies and exon skippers will do anything in Duchenne, ever.
0 · Reply
Florestan
Florestan Jul. 8 at 6:28 PM
$MSCLF I think I may have attracted some ire and stalking from my postings in other boards. If so, might as well have this as the latest post for this board :D.
0 · Reply
Florestan
Florestan Jun. 30 at 3:55 PM
$MSCLF some volume on US side today. Keeping us entertained a bit while waiting out this summer.
0 · Reply
stevetripp
stevetripp Jun. 30 at 3:37 PM
$MSCLF So ' Are we looking at a RS anytime soon?
1 · Reply
bruceleeboy
bruceleeboy Jun. 28 at 1:06 AM
$IMNPQ.DL0922 Annual meetings for $MSCLF, $IVF ($NAYA) & $CLLS are all in. - Satellos got its RS approval and new bd member - Invo Fertility got its approval to increase common stock. (Still one proposal they need buy-in on. They will reconvene July 9th) - Cellectis got its approval to increase ordinary shares, do a share reduction via buyback and a new bd member Immune adjacent companies continue to position themselves for M&A, partnerships, etc.
0 · Reply
Scooter0732
Scooter0732 Jun. 25 at 1:31 PM
$MSCLF interesting
1 · Reply
PennyScam
PennyScam Jun. 23 at 5:09 PM
$MSCLF Good. I hope it’s a massive reverse split. Bigger the better. Enjoy. Cuckoo Penny
0 · Reply
Latest News on MSCLF
No data available.
Florestan
Florestan Jul. 16 at 4:05 PM
$DTIL 3 things to keep in mind for the DMD program which I believe will hit commercialization before the HBV program. 1. It will be a functional cure for about 60% of the patients. Depending on the level of penetration the patient may or may not have to take another drug which I will mention below. 2. If they are going after muscle stem cell editing, they will restore asymmetric division by allowing dystrophin to form the polarity scaffolding (green DMD curve). I'm kind enough to attach an image to show you how this works. 3. The speed of the program. It will only take 3-4 months to show functional benefit if polarity deficit is restored (evident by $MSCLF's peer-reviewed work, and their own P2 timeline). GLTA.
1 · Reply
Florestan
Florestan Jul. 16 at 3:58 PM
$DTIL's preclinical data achieved through muscle stem cell editing and $MSCLF's complete restoration of muscles for the canines through fixing stem cell polarity are pointing to the same directions. You fix DMD through fixing muscle stem cells. Period. Every other approach will fail and that opens up a big short opportunity in every DMD names that aren't targeting muscle stem cells.
0 · Reply
Florestan
Florestan Jul. 16 at 1:27 PM
$MSCLF Satellos Bioscience Inc., developing a small molecule to restore asymmetric division in stem cells in vivo to treat Duchenne, announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer (“CMO”). Dr. Farwell joins Satellos from Dyne Therapeutics (Nasdaq: $DYN), where he most recently served as CMO and medical advisor. Satellos will be submitting IND-enabling package to global regulators this quarter to begin Phase 2 in an RCT setting to prove the hypothesis that the lack of dystrophin in muscle stem cell is causing impaired regeneration, thus explaining the progressively fatal nature of the disease. https://ir.satellos.com/news/news-details/2025/Satellos-Appoints-Dr--Wildon-Farwell-as-Chief-Medical-Officer/default.aspx
0 · Reply
Florestan
Florestan Jul. 14 at 3:54 PM
$MSCLF "Our study provides in vivo validation that dystrophin-deficient MuSCs undergo fewer asymmetric cell divisions, instead favouring symmetric expansion." https://onlinelibrary.wiley.com/doi/full/10.1002/jcsm.13682 This is why none of the gene therapies and exon skippers will do anything in Duchenne, ever.
0 · Reply
Florestan
Florestan Jul. 8 at 6:28 PM
$MSCLF I think I may have attracted some ire and stalking from my postings in other boards. If so, might as well have this as the latest post for this board :D.
0 · Reply
Florestan
Florestan Jun. 30 at 3:55 PM
$MSCLF some volume on US side today. Keeping us entertained a bit while waiting out this summer.
0 · Reply
stevetripp
stevetripp Jun. 30 at 3:37 PM
$MSCLF So ' Are we looking at a RS anytime soon?
1 · Reply
bruceleeboy
bruceleeboy Jun. 28 at 1:06 AM
$IMNPQ.DL0922 Annual meetings for $MSCLF, $IVF ($NAYA) & $CLLS are all in. - Satellos got its RS approval and new bd member - Invo Fertility got its approval to increase common stock. (Still one proposal they need buy-in on. They will reconvene July 9th) - Cellectis got its approval to increase ordinary shares, do a share reduction via buyback and a new bd member Immune adjacent companies continue to position themselves for M&A, partnerships, etc.
0 · Reply
Scooter0732
Scooter0732 Jun. 25 at 1:31 PM
$MSCLF interesting
1 · Reply
PennyScam
PennyScam Jun. 23 at 5:09 PM
$MSCLF Good. I hope it’s a massive reverse split. Bigger the better. Enjoy. Cuckoo Penny
0 · Reply
Florestan
Florestan Jun. 23 at 12:48 AM
$MSCLF Jordan Dubow, CMO, is the person who led Emflaza through FDA approval to become the first pan-genotype DMD treatment in America, becoming the standard of care. This is why you should not take Satellos lightly.
0 · Reply
Florestan
Florestan Jun. 20 at 4:49 PM
$MSCLF notable corporate development: Dr. Loew-Friedrich. She's the former CMO of UCB, a 30B euro company. People like that don't randomly airdrop into the board of a small cap for sport. "Dr. Loew-Friedrich is recognized as the senior clinical leader who shaped UCB into a global powerhouse in neurology and immunology. Serving as executive vice president and chief medical officer until 2024, she led UCB’s worldwide development and regulatory strategy for over two decades, overseeing the global approvals of multiple blockbuster therapies" https://ir.satellos.com/news/news-details/2025/Satellos-Bioscience-Shareholders-Elect-Two-New-Board-Members/default.aspx
0 · Reply
bruceleeboy
bruceleeboy Jun. 19 at 12:10 PM
$MSCLF Annual meeting results https://www.businesswire.com/news/home/20250618536714/en/Satellos-Bioscience-Announces-Results-of-Annual-and-Special-Meeting-of-Shareholders
0 · Reply
Taz69
Taz69 Jun. 19 at 1:24 AM
$MSCLF RS in coming!
1 · Reply
Florestan
Florestan Jun. 18 at 12:02 AM
$MSCLF timeline.
0 · Reply
PennyScam
PennyScam Jun. 17 at 1:39 PM
$MSCLF Looking good. Crazy Kenny
0 · Reply
PennyScam
PennyScam Jun. 17 at 1:35 PM
$MSCLF Great thoughts. I’m not here for Duchenne. Couldn’t care less. I‘m here for future acquisition related to ICO Therapeutics. You know the one. I’m here for the company that they choose to ignore. It’s the company that holds all the value. I love your thoughts Flouride and Alextan. Super awesome. I’m glad people like you are on top of things. Delusional Kenny
0 · Reply
Florestan
Florestan Jun. 16 at 12:00 PM
$MSCLF today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the Duchenne community, listen to families’ experiences, and share updates on its science and mission to regenerate muscle from within. “We’re looking forward to connecting in person with families and advocates who are at the heart of this work,” said Frank Gleeson, Co-founder and CEO of Satellos. “This conference is a powerful reminder of why we’re focused on developing a new approach to treat Duchenne — one that aims to restore the body’s ability to repair muscle.” Attendees can meet members of the Satellos team throughout the event and learn more by visiting the company’s booth in the exhibition hall.
0 · Reply
AlexReddy2021
AlexReddy2021 Jun. 16 at 1:48 AM
$DTIL $MSCLF $SRPT
0 · Reply
Florestan
Florestan Jun. 16 at 1:33 AM
$SRPT it's also pretty clear to me at this stage that most bulls here bought after the 1st death, thinking it's some kind of generational discount. I bring the bad news. And I was mocked before for making these obvious, peer-reviewed statements, that are scientifically true. 1. Microdystrophin does not behave like normal dystrophin. They are way too short. No amount of uDystrophin is good enough. 2. Duchenne is a muscle stem cell division disease. Dumont et al. 2015 has proved this. If you don't fix that part, you can't help Duchenne patients. 3. A successful Duchenne drug must therefore either deliver dystrophin into the stem cells ($DTIL's PBGENE-DMD) or fix stem cell polarity ($MSCLF's SAT-3247). One has shown steady strength increase in mouse, the other doubled grip strength in adult patients. So good luck to all, but remember, biotech is as much luck as it is about understanding mechanism of action and science.
0 · Reply
Florestan
Florestan Jun. 10 at 4:44 PM
$MSCLF 1st half is typical presentation, 2nd half is Q&A which discuss the progress so far and what's coming in the next 3-6 months. Looking busy, and it looks like the first kid could be dosed as early as September. https://youtu.be/G71cCWWyIdg
0 · Reply
Florestan
Florestan Jun. 7 at 10:20 PM
$MSCLF Average increase of 2kg in grip strength in just 28 day of dosing, versus 1kg of increase after 48wks of treatment from exon skipping. Also notable is the age of the patient cohorts. I predict a blow out effect in the kids.
0 · Reply